Company and Stock Identity
How Optellum Connects to the Public Market
- Company structure
- Private company
- Market access
- No current public listing was verified.
- Research focus
- Optellum makes two separate claims and they need separate checks. The first is the clearance, and this site's own FDA record settles it: applicant Optellum, Ltd., clearance K202300, decided 5 March 2021, filed under software that helps assess lesions suspicious for cancer. The second is payment, where the company says the product is reimbursed under the codes 0721T and 0722T. That is the part a hospital finance team will press on, so ask what a real claim actually paid and how often, not what the code allows. The company also says it is live at over 250 sites, which counts installations and not scans read, so ask how many patients actually got a score.
Optellum runs as two companies. Its own site, read on 2026-11-07, gives Optellum Ltd at 5 Kings Meadow, Osney Mead, Ferry Hinksey Road, Oxford, England OX2 0DP, and Optellum Inc at the TMC Innovation Institute, 2450 Holcombe Blvd, Houston, Texas 77021. Its own news page says it closed a Series B round on 8 January 2026 with new money from Woori Venture Partners, the venture arm of Woori Financial Group, and from Healthliant Ventures. No listing was found and none was claimed, so this record says no listing was verified. Checked on 2026-11-07.
Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.
First-Hand Company News
Latest Developments
Optellum lung nodule AI joins the RapidAI platform used by more than 2,500 hospitals
In an announcement dated 20 October 2026, carried on the RapidAI site and datelined Oxford and Houston, Optellum said its Virtual Nodule Clinic with Lung Cancer Prediction AI is now integrated with the Rapid Enterprise Platform from RapidAI. The announcement says the product joins a portfolio of more than 50 RapidAI and third-party clinical solutions and extends the platform into the lung nodule pathway, and that RapidAI technology is used in more than 2,500 hospitals across more than 100 countries. Optellum chief executive Johnathan Watkins is quoted saying the collaboration makes the Virtual Nodule Clinic available to the many health systems already using the platform. Optellum describes the product as the world's first FDA cleared and Medicare reimbursed AI solution for image-based lung cancer risk stratification, reimbursed under the codes 0721T and 0722T. On regulatory status, this site's own FDA directory carries Optellum, Ltd. clearance K202300 for the Optellum Virtual Nodule Clinic, decided 5 March 2021, filed under software that helps assess lesions suspicious for cancer.
Why it matters: This one is more than a plumbing announcement because of what Optellum carries with it. A cleared product that also has billing codes behind it is unusual in imaging AI, and it means a hospital can argue for the tool on money as well as on care quality. Putting it on a platform that is already installed removes the slowest part, which is the IT project. The limit is what a risk score actually changes. Scoring a nodule only helps if a nodule clinic exists to act on the score, and most of the work is pulmonology, thoracic surgery and follow-up scheduling rather than radiology. The reimbursement claim is also the company's own framing, so a finance team should check what a real claim paid rather than what the code allows. The number worth asking for is how many scored patients reached a diagnosis sooner, not how many sites switched it on.
Optellum puts its lung nodule AI inside the RapidAI platform hospitals already run
Optellum said on 20 October 2026 that its Virtual Nodule Clinic, including its Lung Cancer Prediction AI, had been integrated with the RapidAI Rapid Enterprise Platform. Optellum describes Virtual Nodule Clinic as combining patient discovery AI that identifies lung nodules in radiology reports, workflow tools for tracking those patients, and the Lung Cancer Prediction model that scores how likely a nodule is to be cancer. The company says the combination helps care teams prioritise patients and reduce patients lost to follow up. Optellum also describes the product as the first FDA cleared and Medicare reimbursed AI solution for image based lung cancer risk stratification, reimbursed under CPT codes 0721T and 0722T. Johnathan Watkins, chief executive of Optellum, is quoted saying the collaboration makes Virtual Nodule Clinic available to the many health systems that already rely on the Rapid Enterprise Platform. No customer, contract value or launch date is named.
Why it matters: Distribution is the quiet problem in healthcare AI. A tool can be cleared, reimbursed and genuinely good and still sell slowly, because every hospital is a separate security review, a separate integration and a separate budget line. Riding into the building on a platform the hospital already trusts skips most of that, which is why this kind of deal moves more revenue than a new feature usually does. It cuts the other way too: Optellum now depends on another company for reach, and platform relationships get renegotiated. Two claims deserve care. The reimbursement point is real and unusual, because a paid CPT code means a hospital can bill for the work rather than absorb it, but Optellum is the one making the first-in-market claim and nobody has independently checked it. And reducing patients lost to follow up is the outcome worth having, yet the announcement names no site and no number that shows it happened.
Optellum and Coreline Soft agree to connect lung nodule detection to risk scoring in one platform
Optellum said on 13 August 2026 that it and Coreline Soft had announced an intent to collaborate, under which Optellum would integrate Coreline Soft AVIEW Lung Nodule CAD into LungOS, the Optellum platform for thoracic care. Optellum describes the Coreline Soft product as FDA cleared computer aided detection software designed to assist radiologists in detecting lung nodules, and presents the combination as connecting detection with risk assessment and care management in one workflow. Johnathan Watkins, chief executive of Optellum, is quoted calling it highly complementary to what he describes as the company position in reimbursed nodule risk assessment and management, and Jin Kook Kim, chief executive of Coreline Soft, is quoted on contributing to a more connected and scalable lung cancer care model. The announcement states an intent rather than a completed integration, and names no timetable, no financial terms and no customer.
Why it matters: This is two companies admitting they each own half of a job. Detection software tells you a nodule is there; risk software tells you how worried to be. A hospital buying them separately pays twice, integrates twice and ends up with two tools that may disagree, which is a bad position when the disagreement concerns cancer. Joining them is the obvious fix and it is genuinely useful if it happens. The words to hold onto are intent to collaborate. That is not a signed integration, not a product and not a date, and announcements at this stage sometimes go no further. Two more things stay open. Neither company has said what a hospital would pay for the combined product, and nobody has said what happens when the detection tool and the risk tool point in different directions. That handling rule is the part a radiology lead should ask about first.
Optellum wins NIHR funding to test its lung AI inside the NHS over three years
Optellum said on 15 June 2026 that it had been awarded funding by the National Institute for Health and Care Research through its Invention for Innovation programme for a trial named SWIFT LUNG. The company describes it as a prospective, stepped-wedge clinical trial running across multiple NHS sites in England and Scotland over three years, naming NHS Greater Glasgow and Clyde, NHS Highland and Oxford University Hospitals. Optellum says the trial will measure time to triage, time to diagnosis, clinical effectiveness in reducing diagnostic delays, cost effectiveness, and acceptability and implementation, as well as the ability to distinguish benign from malignant nodules. The announcement names a chief investigator at NHS Greater Glasgow and Clyde and quotes clinicians at the participating sites. No funding amount is stated and no results exist yet.
Why it matters: The design is the story. A stepped-wedge trial switches sites over to the new tool at different times, so each site acts as its own comparison, which is about as close to a fair test as a hospital rollout can get. That matters because almost every AI result a buyer is shown is a before-and-after at one site, where the staff knew the tool was being watched. It also matters who is paying. A public research funder has no stake in the answer being yes, so an unfavourable result can actually be published. The limits are real too. Three years is a long time, time to diagnosis is a process measure rather than a survival measure, and a result from British lung cancer pathways does not transfer cleanly to a country with different referral rules. Being funded is also not being finished. Trials end early, and nothing here is evidence yet.
Optellum clears Australian regulators to sell its lung nodule AI there
Optellum said on 26 February 2026 that it had received Therapeutic Goods Administration class IIb approval in Australia for its Virtual Nodule Clinic platform, which it describes as supporting early lung cancer diagnosis through the identification, triage and management of pulmonary nodules. The company says the platform includes its Lung Cancer Prediction AI tool and was already in use in the United States, the European Union and the United Kingdom. On the same page Optellum states that Virtual Nodule Clinic is FDA cleared, CE-MDR marked, TGA approved and UKCA marked. The announcement cites more than 15,000 new lung cancer diagnoses a year in Australia and a five year survival rate of around 27 percent, and carries no quotes.
Why it matters: Four regulators in four markets is a useful signal for a buyer, because each one reviewed the same software against its own rules, and that is harder to arrange than a long customer list. It is worth knowing that the words are not interchangeable. Australia granted a class IIb approval, the United States issued a clearance, and Europe and the United Kingdom work through marking rather than either. They are different processes with different bars, so a company holding all four has cleared four different hurdles, not the same one four times. What none of them establish is a result. Permission to sell is not proof that the software found a cancer sooner or changed what a clinician did, and this announcement offers no Australian data at all. The real test is whether an Australian hospital buys it and reports what changed.
Careers and Qualifications
What to Know Before Applying
Work areas: The careers page is short and specific. On 2026-11-07 it listed two account executive roles in the United States and a senior product manager role in the United Kingdom, run out of the Oxford and Houston offices. It says the company is "assembling the best scientific, engineering & commercial talent" and states its purpose as every lung disease patient diagnosed and treated at the earliest possible stage.
Qualification signal: The open hiring is commercial, not research, so the signal is having sold or launched a tool a hospital had to pay for and bill. Anyone who has carried a product through a billing code and a payer conversation is worth more here than a modelling specialist. On the clinical side, lung nodule experience matters because the product changes who gets a biopsy, and that is a conversation with pulmonology and thoracic surgery, not with radiology alone.
Check current roles at Optellum. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.
Related Healthcare AI Roles
- Imaging Informatics Specialist
- Clinical Validation Specialist
- Regulatory Affairs Specialist, Software as a Medical Device
Training to Compare
- Data Science Institute imaging AI programs ... American College of Radiology, ongoing programs
- Imaging AI Certificate Program ... Radiological Society of North America, six modules per certificate
- Deep Learning for Healthcare Image Analysis workshop ... NVIDIA Deep Learning Institute, 8 hours
Buyer Snapshot
- Best-fit buyer
- Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
- Primary use case
- Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
- Typical deployment
- Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow
Evidence questions
- Was the tool tested prospectively and independently on comparable equipment and patients?
- What are sensitivity, specificity, false positive workload, and time-to-action effects?
- How does performance vary by site, scanner, demographic subgroup, and disease prevalence?
Regulatory and workflow questions
- Which FDA authorization covers the exact product version, modality, and intended use?
- Who retains final clinical responsibility and how is disagreement with the AI handled?
- What post-deployment monitoring and material update notification does the vendor provide?
Data and contract questions
- Where are images and derived data processed and retained?
- Which PACS, RIS, pathology, and EHR integrations are supported in production?
- Can data be used for model improvement, and what controls govern secondary use?
Evidence and Regulation
FDA Clearances on Record
Optellum appears on 1 cleared products in the federal 510(k) record, across 1 device type.
- AI Diagnostic Software for Suspicious Lesions ... 1 cleared product
A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.
What the Published Research Says About This Work
Independent studies on the work itself help separate category evidence from one company's claims.
- AI Stroke Triage ... 24 studies
- AI in Breast Cancer Screening ... 24 studies
- AI in Digital Pathology ... 24 studies